References
- Wirdefeldt K, Adami H-O, Cole P, et al., Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol 2011;26:1–58.
- Shulman JM, De Jager PL, Feany MB, Parkinson's disease: genetics and pathogenesis. Annu Rev Pathol: Mech Dis 2011;6:193–222.
- Del Tredici K, Braak H, Lewy pathology and neurodegeneration in premotor Parkinson's disease. Mov Disord 2012;27:597–607.
- Volpicelli-Daley LA, Luk KC, Patel TP, et al., Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 2011;72:57–71.
- Hauser DN, Hastings TG, Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism. Neurobiol Dis 2013;51:35–42.
- Tufekci KU, Meuwissen R, Genc S, et al., Inflammation in Parkinson's disease. Adv Protein Chem Struct Biol 2011;88:69–132.
- Kruger R, Menezes-Saecker AM, Schols L, et al., Genetic analysis of the alpha2-macroglobulin gene in early- and late-onset Parkinson's disease. Neuroreport 2000;11:2439–42.
- Bell GI, Rall LB, Sanchez-Pescador R, et al., Humanα 2-macroglobulin gene is located on chromosome 12. Somat Cell Mol Genet 1985;11:285–9.
- Poller W, Faber J-P, Klobeck G, et al., Cloning of the human α2-macroglobulin gene and detection of mutations in two functional domains: the bait region and the thiolester site. Hum Genet 1992;88:313–9.
- Benitez BA, Forero DA, Arboleda GH, et al., Exploration of genetic susceptibility factors for Parkinson's disease in a South American sample. J Genet 2010;89:229–32.
- Tang G, Zhang M, Xie H, et al., Alpha-2 macroglobulin I 1000 V polymorphism in Chinese sporadic Alzheimer's disease and Parkinson's disease. Neurosci Lett 2002;328:195–7.
- Xiao Y, Zhang B, Association of the polymorphism in alpha-2 macroglobulin gene with essential tremor and Parkinson's disease. Zhonghua yixue yichuanxue zazhi. Chin J Med Genet 2006;23:84.
- Nicoletti G, Annesi G, Tomaino C, et al., No evidence of association between the alpha-2 macroglobulin gene and Parkinson's disease in a case–control sample. Neurosci Lett 2002;328:65–67.
- Wells G, Shea B, O'connell D, et al., The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000.
- Higgins J, Thompson SG, Deeks JJ, et al., Measuring inconsistency in meta-analyses. BMJ2003;327:557–60.
- Sutton AJ, Abrams KR, Jones DR, et al., Methods for meta-analysis in medical research. J. Wiley 2000.
- DerSimonian R, Laird N, Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–88.
- Hao Y, Xu L, Xie H, The association between both common polymorphisms of alpha 2-macroglobulin gene and Parkinson disease. Chin J Neurol 2002;35:13–15.
- Fung HC, Scholz S, Matarin M, et al., Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol 2006;5:911–6.
- Pankratz N, Wilk JB, Latourelle JC, et al., Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet 2009;124:593–605. doi: 510.1007/s00439-00008-00582-00439. Epub 02008 Nov 00436.
- Simon-Sanchez J, Schulte C, Bras JM, et al., Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 2009;41:1308–12. doi: 1310.1038/ng.1487. Epub 2009 Nov 1315.
- Zhao XP, Xie HJ, Ding SJ, et al., Alpha-2 macroglobulin gene polymorphism in patients with Parkinson's disease and Alzheimer's disease. Chin J Neurol 2004;37:45–47.
- Higuchi S, Matsushita S, Nakane J, et al., Alpha2-macroglobulin gene polymorphisms show racial diversity and are not associated with Alzheimer's disease. Neuroreport 2000;11:1167–71.
- Willi C, Bodenmann P, Ghali WA, et al., Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2007;298:2654–64.
- Doyle KM, Kennedy D, Gorman AM, et al., Unfolded proteins and endoplasmic reticulum stress in neurodegenerative disorders. J Cell Mol Med 2011;15:2025–39.
- Banerjee R, Beal MF, Thomas B, Autophagy in neurodegenerative disorders: pathogenic roles and therapeutic implications. Trends Neurosci 2010;33:541–9.
- Millard S, Lutz F, Li G, et al., Association of cerebrospinal fluid Aβ42 with A2M gene in cognitively normal subjects. Neurobiol Aging 2014;35:357.
- Bruno E, Quattrocchi G, Nicoletti A, et al., Lack of interaction between LRP1 and A2M polymorphisms for the risk of Alzheimer disease. Neurosci Lett 2010;482:112–6.
- Jhoo JH, Kim KW, Lee DY, et al., Association of alpha-2-macroglobulin deletion polymorphism with sporadic Alzheimer's disease in Koreans. J Neurol Sci 2001;184:21–25.
- Guttmacher AE, Collins FS, Nussbaum RL, et al., Alzheimer's disease and Parkinson's disease. N Engl J Med 2003;348:1356–64.
- Nalls MA, Pankratz N, Lill CM, et al., Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet 2014;46:989–93. doi: 910.1038/ng.3043. Epub 2014 Jul 1027.
- Berg D, Lang AE, Postuma RB, et al., Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. The Lancet Neurol. 2013;12: 514–24.